Table 4.
Subgroup analysis of patients in Hp-eradicated group according to the times after eradiaction therapy.
| Characteristics | Group A (1 to 2 years) n = 42 |
Group B (2 to 5 years) n = 24 |
Group C (>5 years) n = 15 |
P value |
|---|---|---|---|---|
| Sex | 0.434 | |||
| Male | 30 (71.4) | 19 (79.2) | 9 (60.0) | |
| Female | 12 (28.6) | 5 (20.8) | 6 (40.0) | |
| Age, yr | 62.38 ± 9.05 | 60.42 ± 8.97 | 62.47 ± 10.25 | 0.679 |
| Smoking history | 0.657 | |||
| Yes | 18 (42.9) | 8 (33.3) | 7 (46.7) | |
| No | 24 (57.1) | 16 (66.7) | 8 (53.3) | |
| Drinking history | 0.873 | |||
| Yes | 16 (38.1) | 10 (41.7) | 5 (33.3) | |
| No | 26 (61.9) | 14 (58.3) | 10 (66.7) | |
| Family history of GC | 0.830 | |||
| Yes | 5 (11.9) | 3 (12.5) | 1 (6.7) | |
| No | 37 (88.1) | 21 (87.5) | 14 (93.3) | |
| CCI | 0.95 ± 1.15 | 1.04 ± 1.00 | 0.67 ± 0.98 | 0.558 |
| Number of clinical consultations | 3.40 ± 3.61 | 4.67 ± 3.58 | 4.47 ± 3.04 | 0.316 |
| Number of endoscopic examinations | 1.76 ± 0.96 | 2.33 ± 0.96 | 2.00 ± 1.25 | 0.097 |
| Time of taking PPI | 0.406 | |||
| ≤1 year | 13 (31.0) | 7 (29.2) | 2 (13.3) | |
| >1 year | 29 (69.0) | 17 (70.8) | 13 (86.7) | |
| Mucosal atrophy | 0.251 | |||
| Mild | 14 (33.3) | 11 (45.8) | 7 (46.7) | |
| Moderate | 20 (47.6) | 12 (50.0) | 8 (53.3) | |
| Severe | 8 (19.0) | 1 (4.2) | 0 (0.0) | |
| Mucosal map-like redness | 0.100 | |||
| Yes | 39 (92.9) | 18 (75.0) | 12 (80.0) | |
| No | 3 (7.1) | 6 (25.0) | 3 (20.0) | |
| Lesion size (mm) | 18.26 ± 13.71 | 13.04 ± 6.56 | 17.07 ± 5.38 | 0.171 |
| Type | 0.366 | |||
| HGIN | 30 (71.4) | 14 (58.3) | 7 (46.7) | |
| WDA | 6 (14.3) | 4 (16.7) | 3 (20.0) | |
| MDA | 4 (9.5) | 6 (25.0) | 5 (33.3) | |
| PDA | 1 (2.4) | 0 (0.0) | 0 (0.0) | |
| SRCC | 1 (2.4) | 0 (0.0) | 0 (0.0) | |
| Ki-67 index | 0.393 | |||
| <50% | 20 (58.8) | 9 (47.4) | 4 (36.4) | |
| ≥50% | 14 (41.2) | 10 (52.6) | 7 (63.6) |